|Common names||MiPLA, Lamide|
|Routes of Administration|
N-Methyl-N-isopropyllysergamide (also known as methylisopropyllysergamide, Lamide and MiPLA) is a lesser-known novel psychedelic substance of the lysergamide class. MiPLA is structurally related to LSD and likely has a similar mechanism of action, working primarily by binding to the serotonin-2A receptor in the brain.
MiPLA was first discovered by Albert Hoffman as a part of the original structure-activity research for LSD. It has recently been researched in greater detail by by a team led by David E. Nichols at Purdue University. MiPLA and its effects are also mentioned in Alexander Shulgin's "Pharmacology Notes #9" and "Pharmacology Notes C". According to Shulgin, human subjects administered MiPLA at doses of 180–300 μg experienced LSD-like psychedelic effects, making it about two- to threefold less potent than LSD.
User reports describe the effects of MiPLA as similar to those of LSD but with some notable differences. It has been described as more mentally and physically oriented than LSD but with a less introspective headspace, accompanied by subtle visuals. It also has a notably shorter duration at around 6 hours and is generally described as less anxiety-provoking than LSD and other lysergamides.
Very little data exists about the pharmacological properties, metabolism, and toxicity of MiPLA. It is highly advised to use harm reduction practices when using this substance.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal status
- 6 See also
- 7 External links
- 8 Literature
- 9 References
The chemical name of MiPLA is methylisopropyllysergamide. MiPLA belongs to a class of organic compounds known as lysergamides, which are a subclass of ergolines (derivatives of the alkaloids found in the ergot fungus). The most prominent member of the lysergamides is LSD, lysergic acid diethylamide.
MiPLA is a structural isomer of LSD. Like LSD, the chemical structure of MiPLA is based on the lysergic acid amide structural skeleton. However, whereas LSD has two ethyl groups bound to the amide nitrogen, MiPLA is substituted with a methyl and isopropyl group.
MiPLA is a chiral compound with two stereocenters at R5 and R8. The differences in psychoactivity between the stereoisomers have not yet been investigated.
As with its structurally related lysergamides, MiPLA principally acts as a 5-HT2A partial agonist, through which it exerts its psychedelic effects. However, the role of these interactions and how they result in the psychedelic experience is unclear.
One study found MiPLA to fully substitute for LSD in rats, with about half the potency of the training drug.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding or correcting it.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Stimulation - Similar to LSD, MiPLA is considered to be primarily stimulating in nature. This is in distinction to other, more commonly used psychedelics such as psilocybin which are more consistent in producing sedation and relaxedness.
- Spontaneous bodily sensations - The "body high" of MiPLA can be described as proportionally intense in comparison to its accompanying visual and cognitive effects. It behaves as a pleasurable, fast-moving, sharp and location specific tingling sensation. For some, it is manifested spontaneously at different unpredictable points throughout the experience, but for most it maintains a steady presence that rises with the onset and hits its limit once the peak has been reached. In comparison to LSD, MiPLA is a little less sharp in the tingling sensations it produces as but is otherwise essentially indistinguishable.
- Physical euphoria - Physical euphoria on MiPLA is not as consistent as it is with substances like stimulants or entactogens, and can just as easily manifest as physical discomfort without any apparent reason.
- Changes in felt bodily form - This effect is often accompanied by a sense of warmth or unity and usually occurs during and up to the peak of the experience or directly afterward. Users can feel as if they are physically part of or conjoined with other objects. This is usually reported as feeling comfortable and peaceful in its sensations.
- Tactile enhancement - Feelings of enhanced tactile sensations are consistently present at moderate levels throughout most MiPLA trips.
- Temperature regulation suppression
- Increased bodily temperature
- Stamina enhancement - Generally mild in comparison to traditional stimulants.
- Bodily control enhancement
- Appetite suppression
- Difficulty urinating
- Increased blood pressure
- Increased heart rate
- Increased perspiration
- Muscle contractions
- Muscle spasms
- Increased libido
- Excessive yawning - This effect is significantly less pronounced than it is with psilocybin and its related compounds, the four-position substituted tryptamines.
- Pupil dilation
- Increased salivation
- Seizure - The possibility of seizures is extrapolated from the seizures that have been reported following the use of LSD. They are thought to mainly be a risk in those who are genetically predisposed to them, particularly while accompanied by physically taxing conditions such as dehydration, fatigue or undernourishment.
- Drifting (melting, breathing, morphing and flowing) - In comparison to other psychedelics, this effect can be described as highly detailed yet cartoon-like in appearance. The distortions are slow and smooth in motion and fleeting in their appearance. This is nearly identical in appearance to the visual drifting which occurs under the influence of LSD.
- After images
- Colour shifting
- Depth perception distortions
- Scenery slicing
- Symmetrical texture repetition
The visual geometry evoked by MiPLA can be described as more similar in appearance to that of LSD, 2C-B or 4-HO-MET than psilocin, LSA or DMT. It can be comprehensively described through its variations as primarily intricate in complexity, algorithmic in form, unstructured in organization, brightly lit, colourful and cartoonish in scheme, organic in feel, flat in shading, soft in its edges, large in size, slow in speed, smooth in motion, either angular or round in its corners, non-immersive in-depth and consistent in intensity. At higher dosages, it consistently results in states of Level 8B visual geometry over Level 8A.
In comparison to LSD specifically, MiPLA's geometry tends to be more rounded in its corners, slightly softer in its edges, warmer in hue, and slightly less intricate in its form. Aside from this, it is otherwise identical in its appearance.
MiPLA is capable of producing a full range of low and high level hallucinatory states in a fashion that is a less consistent and reproducible than that of many other commonly used psychedelics such as psilocin or DMT but considerably more likely to when compared to that of LSD. This can feel similar to the hallucinations which occur with 4-AcO-DMT but tends to occur almost exclusively at heavier doses. Some of these effects include:
- Internal hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots) - This effect is very consistent in dark environments at appropriately high dosages. They can be comprehensively described through their variations as lucid in believability, interactive in style, new experiences in content, autonomous in controllability, geometry-based in style and occasionally of a personal, religious, spiritual, science-fiction, fantasy, surreal, nonsensical or transcendental nature in their overall theme.
- External hallucination (autonomous entities; settings, sceneries, and landscapes; perspective hallucinations and scenarios and plots)
- Analysis enhancement - This effect is consistent in its manifestation and outrospection dominant.
- Conceptual thinking
- Cognitive euphoria
- Novelty enhancement
- Immersion enhancement
- Focus enhancement - This effect is experienced exclusively on low or threshold dosages and feels less forced than it does with stimulants.
- Immersion enhancement
- Motivation enhancement
- Emotion enhancement
- Increased music appreciation
- Increased sense of humor
- Memory suppression
- Time distortion
- Déjà vu
- Thought acceleration
- Thought loops
Anecdotal reports which describe the effects of this compound within our experience index include:
Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational MiPLA use has not been studied in any scientific context and the exact toxic dose is unknown. This is because MiPLA is a research chemical with very little history of human usage.
The current body of anecdotal reports suggests that there are no negative health effects attributed to simply trying the substance by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
However, as is the case for LSD, it is possible that MiPLA can act as a potential trigger for those with underlying psychiatric conditions. Those with a personal or family history of mental illness are generally advised not to use this substance, particularly outside of a supervised medical setting.
It is strongly recommended that one uses harm reduction practices when using this substance.
The LD50 of MiPLA is unknown. Adverse psychological reactions may be more likely to occur at higher doses. Some of these include anxiety, delusions, panic attacks and (more rarely) seizures. Medical attention is usually only needed in the case of severe psychotic episodes or “fake acid” (a counterfeit substance such as 25x-NBOMe or DOx). Administration of benzodiazepines or antipsychotics can help to relieve the negative psychological effects of MiPLA.
Dependence and abuse potential
Like other serotonergic psychedelics, MiPLA is believed to have a low potential for abuse and dependence. This is owing to its structural and pharmacological similarities with LSD. See this section to learn more about the dependence and abuse potential of LSD. It should be noted that all claims related to the abuse potential of MiPLA are preliminary and based on anecdotal (as opposed to clinical) evidence and should be interpreted with caution.
As with LSD, tolerance to the effects of MiPLA forms almost immediately after ingestion. After that, it is assumed to take about 5-7 days for the tolerance to be reduced to half and 14 days to be return to baseline (in the absence of further consumption).
Due to its activity at the 5-HT2A receptor, MiPLA produces cross-tolerance with all psychedelics, meaning that after the consumption of MiPLA all psychedelics will have a reduced effect.
Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when taken with other substances. The following lists some known dangerous combinations, but cannot be guaranteed to include all of them. Independent research should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.
- Lithium - Individuals who take lithium for bipolar disorder or other psychiatric conditions should not take MiPLA. There are numerous anecdotal reports of individuals experiencing seizures and/or psychosis from the combination of LSD and lithium. Due to MiPLA's chemical similarity to LSD, it is assumed to carry a similar risk.
- Tramadol - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures, particularly in predisposed individuals.
- Stimulants - Stimulants affect many parts of the brain. Combined with psychedelics, stimulation can turn into uncontrollable anxiety, panic, thought loops and paranoia. This interaction may cause elevated risk of psychosis.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
MiPLA is not scheduled under the UN Convention on Psychotropic Substances. It is considered to exist in a legal grey area throughout most of the world, meaning that it might not be specifically illegal but individuals may still be charged for its possession under certain circumstances such as under analogue laws and with the intent to sell or consume.
- Austria: MiPLA is technically not illegal but it may fall in the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich) as an analogue of LSD.
- United States: MiPLA is not scheduled but may be considered to be an analogue of LSD, which would make it illegal to possess for human consumption under the Federal Analogue Act.
- Halberstadt, A. L., Klein, L. M., Chatha, M., Valenzuela, L. B., Stratford, A., Wallach, J., ... & Brandt, S. D. (2018). Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA). Psychopharmacology, 1-10. http://dx.doi.org/10.1007/s00213-018-5055-9
- Nichols, D. E. (2001). LSD and its lysergamide cousins. The Heffter Review of Psychedelic Research. Santa Fe, New Mexico: Heffter Research Institute, 80-87.
- Halberstadt, A.L., Klein, L.M., Chatha, M. et al. Psychopharmacology (2018). http://dx.doi.org/10.1007/s00213-018-5055-9
- https://erowid.org/chemicals/lsd/lsd_interactions.shtml | LSD Interactions by Erowid
- Wanderli. "A Nice Little Trip to the Hospital: An Experience with Lithium & LSD (ID 83935)". Erowid.org. Oct 3, 2010.
- MissDja1a. "Having a Seizure and Passing Out: An Experience with Lithium & LSD (ID 75153)". Erowid.org. Dec 16, 2008.
- Reddit account of seizure on LSD + Lithium | https://www.reddit.com/r/Psychonaut/comments/17uspp/please_read_a_cautionary_tale_concerning_lsd/
- Talaie, H., Panahandeh, R., Fayaznouri, M. R., Asadi, Z., & Abdollahi, M. (2009). Dose-independent occurrence of seizure with tramadol. Journal of medical toxicology, 5(2), 63-67. doi:10.1007/BF03161089